Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment

American Journal of Hematology

Volumn 83, Issue 2, 2008, Pages 165-166

  Unal, Sule ^a   Güçer, Safak ^a   Kale, Gülsev ^a   Besbas, Nesrin ^a   Özen, Seza ^a   Gümrük, Fatma ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIBIOTIC AGENT; COLCHICINE; CYCLOPHOSPHAMIDE; DEFERIPRONE; DEFEROXAMINE; FERRITIN; METHYLPREDNISOLONE; PREDNISOLONE;

AMINO ACID SUBSTITUTION; ANAPHYLACTOID PURPURA; ARTHRITIS; ARTICLE; ATELECTASIS; BARIUM ENEMA; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DNA DETERMINATION; ERYTHEMA; ERYTHROCYTE TRANSFUSION; FAMILIAL MEDITERRANEAN FEVER; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; INTUSSUSCEPTION; IRON CHELATION; IRON OVERLOAD; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PLEURA EFFUSION; PRIORITY JOURNAL; PURPURA; RESPIRATORY FAILURE; RISK FACTOR; SCHOOL CHILD; SPLENECTOMY; SYMPTOM; THALASSEMIA MAJOR; THORAX RADIOGRAPHY; VASCULITIS;

AMINO ACID SUBSTITUTION; BETA-THALASSEMIA; CHILD; DNA; FAMILIAL MEDITERRANEAN FEVER; HUMANS; IRON CHELATING AGENTS; MALE; PURPURA, SCHOENLEIN-HENOCH; PYRIDONES; SPLENECTOMY;

EID: 38349171291     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21052     Document Type: Article

References (19)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-755.
2. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-1295.
3. Anderson LJ, Wonke N, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in b-thalassaemia. Lancet 2002;360:516-520.
4. Piga A, Gaglioti C, Fogliaccio E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica 2003;88:489-496.
5. Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol 2000;108:305-312.
6. al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224-229.
7. Berkovitch M, Laxer RM, Inman R, et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994;343:1471-1472.
8. Mehta J, Singhal S, Revankar R, et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1. Lancet 1991;337:298.
9. Castriota-Scanderbeg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Haematol 1997;96:254-255.
10. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936-941.
11. Coppo R, Amore A, Gianoglio B. Clinical features of Henoch-Schonlein purpura. Italian Group of Renal Immunopathology. Ann Med Interne (Paris) 1999;150:143-150.
12. Rai A, Nast C, Adler S. Henoch-Schonlein purpura nephritis. J Am Soc Nephrol 1999;10:2637-2644.
13. Nakamura T, Matsuda T, Kawagoeu Y, et al. Plasmapheresis with immunosuppressive therapy vs immunosuppressive therapy alone for rapidly progressive anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Nephrol Dial Transplant 2004;19:1935-1937.
14. Ezer U, Gulderen F, Culha VK, et al. Immunological status of thalassemia syndrome. Pediatr Hematol Oncol 2002;19:51-58.
15. Bowlus CL. The role of iron in T cell development and autoimmunity. Autoimmun Rev 2003;2:73-78.
16. Castellino G, Govoni M, Trotta F. Rheumatoid arthritis in β-thalassaemia trait. Rheumatology (Oxford) 2000;39:1286-1287.
17. Montecucco C, Caporali R, Rossi S, Epis O. Rheumatoid arthritis in β-thalassaemia trait. Rheumatology (Oxford). 1999;38:1021-1022.
18. Ozdogan H, Arisoy N, Kasapcapur O, et al. Vasculitis in familial Mediterranean fever. J Rheumatol 1997;24:323-327.
19. Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean fever: Do they predispose to inflammation? J Rheumatol 2003;30:2014-2018.